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Abstract: 
Hepatitis-associated aplastic anemia (HAAA) is a variant of acquired aplastic anemia and characterized by 
bone marrow failure that follows the development of acute hepatitis. We herein report a rare case of HAAA 
with rapid progression of liver fibrosis due to repeated hepatitis. A pathological examination of liver speci-
mens revealed liver fibrosis progression over a short period. Immunosuppressive therapy with cyclosporine 
effectively cured both the pancytopenia and hepatitis. Our case suggests that the pathological examination of 
the liver tissue is useful for determining a treatment plan and that immunosuppressive therapy is a promising 
treatment for both aplastic anemia and persistent hepatitis. 
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Introduction 
Aplastic anemia (AA) is a serious blood disorder resulting 
from failure of the bone marrow to produce blood cells. Al-
though most cases of AA are classified as idiopathic, some 
patients develop symptoms after an episode of acute hepati-
tis. If the onset of AA is clinically related to acute liver in-
jury, it is called hepatitis-associated aplastic anemia 
(HAAA). HAAA accounts for 4% to 10% of AA cases in 
East Asia (1), and the presumed causes of acute hepatitis is 
viral infection, such as by hepatitis A virus, hepatitis B vi-
rus, hepatitis C virus, parvovirus B19, cytomegalovirus, Ep-
stein bar virus, and transfusion-transmitted virus (2-7), but 
the causative virus is not identified in most HAAA 
cases (8, 9). In general, pancytopenia appears two or three 
months after acute hepatitis attack (9, 10), and the develop-
ment of AA can be fatal if not treated in a timely man-
ner (8, 11). 
We herein report a case of HAAA accompanied by rapid 
progression of liver fibrosis due to repeated hepatitis. In this 
case, immunosuppressive therapy was effective against the 
severe hepatitis as well as the AA. 
Case Report 
A 26-year-old man was referred to our institute for re-
peated hepatitis and a blood cell disorder and admitted. One 
year before admission to our hospital, he developed acute 
hepatitis with elevated levels of aspartate transaminase 
(AST, 1,750 U/L), alanine transaminase (ALT, 3,110 U/L), 
and total bilirubin (T-bil, 8.9 mg/dL) after receiving a flu 
shot. Although a further examination, including a liver bi-
opsy, was performed, the cause of the liver dysfunction re-
mained unclear, and the laboratory data improved without 
treatment (Fig. IA). Six months after the initial episode, the 
patient was admitted to another hospital due to recurrence of 
the liver dysfunction with elevated AST (957 U/L) and ALT 
(1 ,970 U/L) levels, as well as leukocytopenia and thrombo-
cytopenia. The cause of the blood disorder, however, was 
still unclear; the results of tests for typical viruses, such as 
hepatitis A, B, C, and E, and cytomegalovirus, and for vari-
ous autoantibodies were negative. His liver dysfunction 
again improved without treatment, but the leukocytopenia 
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Figure 1. Changes in laboratory values in the course of hepatitis. (A) The first episode. (B) The 
second episode. (C) The third episode. WBC: white blood cell count, PLT: platelet, AST: aspartate 
transaminase, ALT: alanine transaminase 
and thrombocytopenia persisted even after discharge from 
the hospital (Fig. lB). Seven months after the second epi-
sode, he presented to his primary care physician with gen-
eral fatigue and was diagnosed with recurring liver dysfunc-
tion (AST 434 U/L and ALT 1,017 U/L). He was referred to 
our institute for a re-examination of his liver dysfunction. 
He had no remarkable medical history other than the re-
peated liver dysfunction and persistent leukocytopenia and 
thrombocytopenia. He had received a flu shot one month be-
fore visiting our hospital. All vital signs were normal, and 
there was no evidence of jaundice. His abdomen was flat, 
and neither hepatomegaly nor ascites were observed. The 
laboratory evaluation revealed abnormalities in the liver 
panel results (AST 501 U/L, ALT 1,165 U/L, alkaline phos-
phatase 429 U/L, and y-glutamyl transpeptidase 103 U/L). 
The T-bil, albumin, and prothrombin time values were 
within the normal ranges. A complete blood count revealed 
the following values: white blood cell (WBC) 2.35xl03/µL, 
neutrophils 0.94xl03/µL, hemoglobin 14.0 g/dL, reticulocyte 
8.0x ]04/µL, and platelets 3x )04/µL. The serologic test results 
were negative for hepatitis B surface antigen, hepatitis C vi-
rus IgG, cytomegalovirus IgM, and Epstein-Barr virus IgM 
antibodies, as well as for antinucleic and antimitochondrial 
antibodies. The values of the representative laboratory ex-
aminations are summarized in the Table. Abdominal ultra-
sonography and contrast-enhanced computed tomography re-
vealed mild splenomegaly but no specific findings in the 
liver (Fig. 2). 
To evaluate the pathologic features of the liver tissue, we 
performed a transjugular liver biopsy and compared the 
2 
sample with the liver biopsy specimen that had been col-
lected at the previous hospital when he had had liver dys-
function one year before. While lymphocyte infiltration was 
prominent in the previous sample (Fig. 3A, B), most of the 
lymphocytes had disappeared and been replaced by histio-
cytes (Fig. 4A, B). Interestingly, bridging hepatic necrosis of 
the portal area and progression of the fibrosis in the centri-
lobule were observed in the second biopsy sample, whereas 
fibrotic changes were not observed in the first sample 
(Fig. 4C, D). These findings suggest that the repeated severe 
hepatic inflammation led to the rapid progression of liver fi-
brosis. 
Next, we examined his bone marrow function to elucidate 
the cause of the leukocytopenia and thrombocytopenia. Scin-
tigraphy imaging showed hypoplastic bone marrow with a 
diffuse reduced uptake of ' ' 'In-tracer in the whole body 
(Fig. 5A). A bone marrow biopsy study showed severe hy-
pocellularity with a nucleated cell density of 10% and fatty 
replacement (Fig. 5B). In addition, small populations of par-
oxysmal nocturnal hemoglobinuria (PNH)-type cells were 
identified among granulocytes and red blood cells in the pe-
ripheral blood by flow cytometry. Taken together, these find-
ings led us to diagnose the patient with HAAA of unknown 
origin. 
Given the rapid progression of the liver fibrosis and the 
presence of PNH-type cells, treatment with cyclosporin was 
introduced on day 20 of hospitalization. The liver enzyme 
levels promptly decreased to the normal range, and the 
WBC and platelet counts increased after beginning cy-
closporin treatment. After discharge on day 29 of hospitali-
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Table. Laboratory Findings on Admission. 
Complete blood cell count 








































































WBC: white blood cell, Neutro: neutrophil, RBC: red blood cell, Pit: platelet, PT: prothrom-
bin time, INR: international normalized ratio, APlT: activated partial thromboplastin time, 
AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydroge-
nase, ALP: alkaline phosphatase, ggTP: gamma glutamyl transpeptidase, T-bil : total bili rubi n, 
TP: total protein, Alb: albumin, CRP: C-reactive protein, HBsAg: hepatitis B surface antigen, 
HBsAb: hepatitis B surface antibody, HBcAb: hepatitis B core antibody, HCVAb: hepatitis C 
virus antibody, EBV: Epstein-Bar virus, YCA: viral-capsid antigen, EBNA: Epstein-Bar nu-
clear antigen, CMV: cytomegalovirus 
Figure 2. Images of abdominal contrast-enhanced computed tomography obtained on the day of 
hospitalization are shown. The left and right panels show the axial and coronal views of the abdomen, 
respectively. 
zation, he continued treatment with cyclosporin without re-
currence of liver dysfunction (Fig. l C). 
3 
Discussion 
Since 1955, when Lorenz et al. (12) reported the first two 
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A B 
Figure 3. Images of hematoxylin & eosin (H&E) -stained liver biopsy specimen collected at the 
previous hospital [original magnification, (A) xlOO, (B) x400]. 
A B 
C D 
Figure 4. Images of liver biopsy specimens at the second relapse. (A) (B) H&E-stained sections. (C) 
(D) Silver impregnation-stained section [Original magnification, (A) (C) xlOO, (B) (D) x400]. 
cases, HAAA has been established as one of the main clini-
cal forms of AA, and usually occurs several months after an 
episode of acute hepatitis (9, 10). The assumed etiology of 
the preceding hepatitis is viral infection, but the causal virus 
is usually not identified. In the present case, the patient had 
4 
received a flu vaccine one month before the onset of hepati-
tis. Sasaki et al. reported two cases of autoimmune hepatitis 
that developed after receiving a flu shot (13). This finding, 
along with the first episode of acute hepatitis appearing after 
a flu shot, suggested that an excessive immune response to 





Figure 5. An examination of the bone marrow function. (A) Bone scintigraphy with 111In-tracer. (B) 
Representative image of a bone marrow biopsy specimen stained with H&E (Original magnification, 
xlOO). 
the vaccination might have caused severe hepatitis. The trig-
ger of the second episode of hepatitis with leukocytopenia 
and thrombocytopenia, however, was still unclear. 
Autoimmune hepatitis was a differential diagnosis of 
hepatitis in this case because rapid progression of fibrosis 
was observed and the hepatitis onset was suspected to have 
been triggered by a flu shot. However, an antinucleic anti-
body test was negative, and the serum immunoglobulin G 
level was within the normal range. According to the Interna-
tional Autoimmune Hepatitis Group Criteria, his pretreat-
ment score was 3 points (ALP/ALT ratio +2, hepatitis viral 
markers +3, drug history +1, alcohol intake +2, liver histol-
ogy -5). HAAA was thus more likely than autoimmune 
hepatitis in the present case. 
As a case of HAAA with repeated acute hepatitis has 
never, to our knowledge, been reported, we performed a sec-
ond liver biopsy after a one-year interval to reevaluate the 
hepatic inflammation and fibrosis. Although no typical his-
tologic features of hepatitis related to HAAA have yet been 
proposed (14), we observed two important differences be-
tween the two biopsy timepoints. First, the lymphocytes in-
filtrating at the portal regions observed at the first biopsy 
had disappeared and been replaced by histiocytes. These 
findings imply that the first liver biopsy represented the in-
itial stage of hepatitis, while the second liver biopsy repre-
sented the chronic stage. Second, while no fibrotic changes 
were observed in the first sample, clear bridging fibrosis 
was detected in the second sample. This finding suggests 
that repeated hepatic inflammation caused the rapid progres-
sion of liver fibrosis in just one year. 
Treatment for AA depends on the patient's stage. Al-
though the evidence for treating patients with mild AA is 
lacking, watchful observation is proposed because some pa-
tients improve without any therapeutic intervention. For pa-
tients with severe AA, bone marrow transplantation is a rep-
5 
resentative curative therapy with a favorable prognosis, but 
immunosuppressive therapy using cyclosporin and/or an-
tithymocyte globulin is considered instead for patients older 
than 40 years old or those without HLA-identical sib-
lings (15). Immunosuppressive therapy is especially effective 
for AA patients with PNH-type cells, which lack the expres-
sion of glycosylphosphatidylinositol anchor membrane pro-
teins, such as CD55 and CD59 (16, I 7). However, immuno-
suppressive therapy was also reported to be effective in sev-
eral HAAA cases, suggesting that immune-mediated patho-
genesis is associated with the onset of HAAA (7, 18). In the 
present case, cyclosporine was administered as first-line 
therapy, because his AA was classified as mild but rapidly 
progressive. As his pancytopenia rapidly recovered after that, 
we did not administer further treatment, such as antithymo-
cyte globulin. Notably, his hepatic inflammation was simul-
taneously ameliorated, suggesting that the hepatic inflamma-
tion had been induced by the same immunoreactive mecha-
nism as the bone marrow dysfunction. 
In conclusion, pathologic examinations of the liver tissue 
at multiple time-points were useful for determining a treat-
ment plan in this case of HAAA with repeated liver dys-
function. Because hepatitis observed in the patients with 
HAAA occurs through immunogenic mechanisms, immuno-
suppressive therapy may be effective not only for AA but 
also for persistent or repeated hepatic inflammation, espe-
cially in PNH-type cell-positive cases. 
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